ClinicalTrials.gg
Not yet recruitingNCT06292143AI4HOPE2Updated Feb 2, 2026

AI4HOPE Pilot Study 2 Digital Dementia Care Planning

An interventional study of Advance Care Planning Toolkit in Dementia, sponsored by University of Bonn. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-02-02.

Sponsored by University of Bonn · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Sex
All
01

Study summary

This pilot study will test a digital care planning decision support system for patients with dementia.

Read the detailed description

The clinical study is part of an EU-funded project on the use of artificial intelligence for patients with dementia. This study will test a digital toolkit for advance care planning and decision making for patients with dementia and pilot-test this digital support system for feasibility and acceptability.

Other workpackages of the AI4HOPE project will design a digital technology platform to provide relevant, timely and appropriate information for people with dementia and their carers, and to facilitate them to document their goals, wishes, and preferences for future care.

Patients with mild to moderate dementia will be recruited for the pilot study in the six participating countries. The study population includes all types of dementia without stratification, as the aim of the study is to develop a digital technology platform to facilitate ACP for clinical practice in any patient with cognitive impairment from any type of dementia.

Even though the digital platform could be adapted to be useful for patients with advanced dementia and more severe cognitive impairment, or for use just by their families, the pilot study will recruit only patients with mild or moderate dementia, who will still be able to provide informed consent, and who will be able to self-assess for patient-related outcome or patient-related experience measures to inform the assessment of the digital technology platform.

Patients with dementia treated in the participating study centers will be screened for inclusion criteria and, if suitable will be invited to participate. The study will be performed for up to 90 days, with optional extension to 180 days according to patients' preferences.

Patients with baseline data and at least one interaction with the digital platform and data completed before and after that interaction will be included in the evaluation.

02

Conditions studied

  • Dementia

Browse trials for

03

In context

Dementia

2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.

This study's planned enrollment of 150 is above the median of 90 across 1,761 interventional studies indexed under Dementia.

Browse Dementia studies →

Lead sponsor

University of Bonn is the lead sponsor of 39 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Mild or moderate dementia of any type
  • (MoCA) score of 16-25
  • Living at home, or in residential or nursing home care
  • Receiving adequate social support

Exclusion criteria

Exclusion Criteria:

  • Moderate/severe cognitive impairment ( \< 16)
  • No cognitive impairment (MoCA >25)
  • Inpatient or acute hospital treatment
  • Infectious diseases or lokal skin conditions preventing the use of wearable body sensors
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Other
    Advance Care Planning toolkit

    Provision of access to the digital ACP (Advance Care Planning) platform to patients and caregivers, baseline assessment with the ACP digital platform on day 0. Information to guide decision making around care and treatment preferences are accessed by patients and carers on days 1 to 7. Where desired, care and treatment preferences are recorded. Evaluation of usefulness and burden of the digital platform for ACP on day 7. Content stored on digital platform for ACP shared across care settings to those involved in care of participant on day 8 to 29. Evaluation of usefulness and burden of the digital platform for ACP, participant and carer experience of completion. Initial exploration of impact on communication between health and social care professionals, access to timely information to inform clinical decision making, and efficiency savings (e.g. reduction in paper forms and duplication, less time chasing information) on day 90.

    Other: Advance Care Planning Toolkit

Interventions

  • OtherAdvance Care Planning Toolkit

    Participants or their caregivers will access the digital platform for advance care planning

06

What researchers measure

Primary outcomes

  1. Feasibility and acceptability of digital ACP-platform, the Dementia Journey Companion (DJC)

    Participant feedback on feasibility, usefulness and burden of ACP-platform; acceptability of content included in the ACP-platform for participantd, user satisfaction with conversational support and suc-cess rate in achieving communicative goals, answering questions and providing guidance.

    Time frame: 30 days

Secondary outcomes

  1. Effect of DJC on documentation of ACP

    Rating of benefit by health care professionals.

    Time frame: 30 days

  2. Completion rate of preference documentation

    Completion rate of preference documentation across domains (daily living, medical, end-of-life) and frequency of use; frequency of chatbot interactions; number of memories, stories, and preferences documented.

    Time frame: 30 days

  3. Assessment of pain, distress and anxiety

    Assessment of pain, distress and anxiety (PROM as part of assessment toolkit).

    Time frame: 30 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Aug 2027, 18 months later.

Of 862 non-industry interventional studies with no phase under Dementia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 18 months is below that.

Counting every sponsor, half of 908 studies reached it within 25 months; a quarter within 11 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2024
First posted
Mar 4, 2024
StartEst.
Feb 2026
Primary completionEst.
Aug 2027
CompletionEst.
Dec 2027
Last update
Feb 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06292143
Lead sponsor
University of Bonn
Collaborators
University College Cork, University of Leeds, Fundacion Intras, Universidade do Porto, University Medical Centre Maribor
Responsible party
Lukas Radbruch (Director Department of Palliative Medicine, University Hospital Bonn, University Hospital, Bonn) — Principal investigator
First posted
Mar 4, 2024
Start date
Feb 2026 (estimated)
Primary completion
Aug 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Feb 2, 2026

Study contacts

Lukas Radbruch, MD
Contact
lukas.radbruch@ukbonn.de
+4915158233747
Holger Brunsch, Dr.
Contact
holger.brunsch@ukbonn.de
+49 228 287 10309
Lukas Radbruch, MD
principal investigator · Department of Palliative Medicine, University Hospital Bonn

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion